World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification
Authors: Devan Kansagara, Linda L. Humphrey, Amir Qaseem
Journal: Annals of Internal Medicine (2019)

Letters16 April 2019World Health Organization Guidelines on Medicines for Diabetes Treatment IntensificationDevan Kansagara, MD, MCR, Linda L. Humphrey, MD, MPH, and Amir Qaseem, MD, PhD, MHADevan Kansagara, MD, MCROregon Health & Science University and Veterans Affairs Medical Center, Portland, Oregon (D.K.)Search for more papers by this author, Linda L. Humphrey, MD, MPHOregon Health & Science University, Portland, Oregon (L.L.H.)Search for more papers by this author, and Amir Qaseem, MD, PhD, MHAAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0069 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Good and colleagues that it is important to carefully consider resource constraints and the clinical setting in addition to patient factors when managing persons with diabetes. As our commentary stated, these considerations were probably central to the World Health Organization's decision to recommend sulfonylureas as the second-line treatment option for most patients (1). We are fortunate that many sectors of the U.S. health care system have access to various second-line diabetes treatment options that are associated with lower risk for hypoglycemia and that may have cardiovascular benefits for some patients. Newer agents may be ...Reference1. Humphrey LL, Kansagara D, Qaseem A; High Value Care Committee of the American College of Physicians. World Health Organization guidelines on medicines for diabetes treatment intensification: commentary from the American College of Physicians High Value Care Committee. Ann Intern Med. 2018;169:398-400. [PMID: 30178054]. doi:10.7326/M18-1148 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Oregon Health & Science University and Veterans Affairs Medical Center, Portland, Oregon (D.K.)Oregon Health & Science University, Portland, Oregon (L.L.H.)American College of Physicians, Philadelphia, Pennsylvania (A.Q.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-1148. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWorld Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee Linda L. Humphrey , Devan Kansagara , Amir Qaseem , and World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification Chester B. Good , Norman R. Kolb , and Mark Meyer Metrics Cited byThe effect of dapagliflozin on myocardial ischemia–reperfusion injury in diabetic ratsEvaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things TechnologyDeterminants of Increased Fibrinogen in COVID-19 Patients With and Without Diabetes and Impaired Fasting GlucoseGlycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients 16 April 2019Volume 170, Issue 8Page: 583-584KeywordsDisclosureGlobal healthHealth careHypoglycemiaTreatment guidelinesType 2 diabetesWeight gain ePublished: 16 April 2019 Issue Published: 16 April 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...